Home  /  Resource Library  /  The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial

The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial

Study examined the cost effectiveness of CAR T therapy axicabtagene ciloleucel for treating relapsed large cell lymphomas.